Intravenous lacosamide as replacement for oral lacosamide in patients with partial‐onset seizures

@article{Biton2008IntravenousLA,
  title={Intravenous lacosamide as replacement for oral lacosamide in patients with partial‐onset seizures},
  author={Victor Biton and William E Rosenfeld and John Gregory Whitesides and Nathan B Fountain and Nerija Vai{\vc}ienė and G. David Rudd},
  journal={Epilepsia},
  year={2008},
  volume={49}
}
Purpose: This multicenter, double‐blind, double‐dummy, randomized, inpatient trial evaluated the safety, tolerability, and pharmacokinetics of intravenous lacosamide as replacement for oral lacosamide in patients with partial‐onset seizures. 
Intravenous lacosamide as short‐term replacement for oral lacosamide in partial‐onset seizures
TLDR
The safety and tolerability of an intravenous formulation of lacosamide infused over 10, 15, and 30 min as short‐term replacement for oral Lacosamide in patients with partial‐onset seizures is evaluated.
Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide‐naive patients with partial‐onset seizures
Purpose:  To examine the safety and tolerability of rapidly initiating adjunctive lacosamide via a single intravenous loading dose followed by twice‐daily oral lacosamide in lacosamide‐naive adults
Adjunctive lacosamide for partial‐onset seizures: Efficacy and safety results from a randomized controlled trial
TLDR
To evaluate the efficacy and safety of lacosamide when added to one to three concomitant antiepileptic drugs (AEDs) in patients with uncontrolled partial‐onset seizures.
Lacosamide and Epilepsy
TLDR
It is found that lacosamide is an effective agent for adjunctive treatment of refractory partial‐onset seizures and its adverse drug effects were mild and infrequently reported in the literature.
Lacosamide in status epilepticus: Systematic review of current evidence
The intravenous formulation of lacosamide (LCM) and its good overall tolerability and safety favor the use in status epilepticus (SE). The aim of this systematic review was to identify and evaluate
Outcome of cancer‐related seizures in patients treated with lacosamide
TLDR
The clinical experience with lacosamide in neuro‐oncological patients is described, which has proven to be effective to control seizures, including acute conditions such as status epilepticus.
Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy
TLDR
A patient with nonconvulsive status epilepticus who was successfully treated with intravenous lacosamide is described, a novel anticonvulsant drug available as infusion solution.
Lacosamide in patients with pharmacoresistant epilepsy
TLDR
Lacosamide is one of the newest drugs of the antiepileptic armamentarium, and it is expected to compete directly with compounds that are currently used for adjunctive therapy in adults with refractory partial epilepsy.
Lacosamide as a new add-on therapy for the treatment of partial-onset seizures
TLDR
LCM provides a novel mechanism of action and favorable pharmacokinetic profile that includes absolute bioavailability, low protein binding, renal excretion, lack of hepatic enzyme induction or inhibition, low potential for drug–drug interactions, and a relatively long half-life.
Lacosamide: A Review of Its Use as Adjunctive Therapy in the Management of Partial-Onset Seizures
TLDR
In three randomized, double-blind, placebo-controlled, multicentre studies in adults and adolescents with partial-onset seizures, adjunctive therapy with oral lacosamide generally reduced the frequency of seizures to a significantly greater extent than placebo, with antiepileptic efficacy sustained following longer-term treatment in this patient population.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset Seizures
Summary:  Purpose: To evaluate the efficacy and safety of lacosamide when added to 1 or 2 antiepileptic drugs (AEDs) in adults with uncontrolled partial‐onset seizures, and assess plasma
New formulations of drugs in epilepsy.
TLDR
New formulations of anti-epileptic drugs profiles include Tegretol-XR (TXR) and Carbatrol (CBTL), two extended-release preparations of carbamazepine (CBZ), which allow twice daily administration, minimising drug toxicity and improving efficacy.
SPM-927 (Schwarz Pharma).
TLDR
SPM-927, synthesized by researchers at the University of Houston, for the potential treatment of epilepsy and neuropathic pain is developed by Schwarz Pharma under license from Harris FRC.
Dissociative and Associated Psychopathological Symptoms in Patients with Epilepsy, Pseudoseizures, and Both Seizure Forms
Summary:  Purpose: A controversy currently exists regarding the significance of dissociation and conversion in the pathogenesis of pseudoepileptic seizures. After the abolition of the term
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)
TLDR
Information presented on drugs in preclinical and clinical development, including carabersat, CGX-1007 (Conantokin-G), pregabalin, retigabine (D-23129), safinamide, SPD421 (DP-VPA), SPM 927, talampanel and valrocemide are summarized.
Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX)
TLDR
The current (EILAT IX) manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development, including brivaracetam, carisbamate, eslicarbazepine acetate and YKP-3089.
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
TLDR
This article summarizes the information presented on drugs in preclinical and clinical development, including AWD 131-138, DP-valproate, harkoseride, LY300164, NPS 1776, NW 1015, pregabalin, remacemide, retigabine, rufinamide and valrocemide.
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
TLDR
This article summarizes the information presented on drugs in development, including atipamezole, BIA-2-093, fluorofelbamate, NPS 1776, pregabalin, retigabine, safinamide, SPM 927, stiripentol, talampanel,ucb 34714 and valrocemide, as well as updates on second-generation AEDs.
Efficacy and safety of adjunctive oral la - cosamide for the treatment of partial - onset seizures in patients with epilepsy . ( Abstract )
  • Neurology
  • 2005
Safety , tolerability , and pharmacokinetics of intravenous lacosamide as replacement for oral lacosamide in subjects with partial seizures . ( Abstract )
  • Neurology
  • 2005
...
1
2
...